Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Liver Regeneration01:24

Liver Regeneration

The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is responsible...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Erratum to 'BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update' [J Hepatol (2026) 631-654].

Journal of hepatology·2026
Same author

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial).

Alimentary pharmacology & therapeutics·2026
Same author

Correction: Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages.

Frontiers in immunology·2026
Same author

A three-gene resistome signature as a prognostic tool in hepatocellular carcinoma.

Annals of hepatology·2025
Same author

Epidemiology, clinical, molecular features, and prognosis of early-onset biliary tract cancer: A systematic review and meta-analysis.

JHEP reports : innovation in hepatology·2025
Same author

Cholangiocarcinoma 2026: status quo, unmet needs and priorities.

Nature reviews. Gastroenterology & hepatology·2025

関連する実験動画

Updated: May 24, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

肝細胞性がん (HCC) は肝細胞性がん (HCC) と呼ばれる.

Alejandro Forner1, Josep M Llovet, Jordi Bruix

  • 1Barcelona Clinic Liver Cancer group, Liver Unit, Hospital Clínic Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain.

Lancet (London, England)
|February 23, 2012
PubMed
まとめ

超音波検査による肝細胞癌の監視は,切除や移植などの潜在的に治療的な治療の早期発見を助けます. 先進的な症例では,化学栓塞治療や分子標的治療が有益であり,生存率を改善する可能性があります.

科学分野:

  • 肝臓病理学 肝臓病理学
  • 腫瘍学 腫瘍学
  • 胃腸内科 胃腸内科

背景:

  • 肝細胞癌 (HCC) は,世界中で癌による死亡の主な原因です.
  • 肝硬変は,HCCを発症するリスクを大幅に増加させます.
  • 定期的なスクリーニングによる早期発見は,患者のアウトカムを改善するために不可欠です.

研究 の 目的:

  • 肝細胞癌の現在の監視戦略をレビューする.
  • 疾患の段階に基づいて,HCCの様々な治療方法について議論する.
  • HCC管理と進行中の研究における進歩を強調する.

主な方法:

  • HCCの監視のための現在の臨床ガイドラインのレビュー.
  • 切除,肝臓移植,アブレーション,化学栓塞の治療結果の分析.
  • 先進的なHCCにおける分子標的療法に関する証拠の評価.

主要な成果:

  • 高リスクの患者 (肝硬変) の場合,半年ごとに超音波検査を行うことが推奨されます.
  • 治癒的治療 (切除,移植,切除) は,初期段階の腫瘍に対して最も効果的です.
  • 化学エンボリゼーションとソラフェニブ (分子標的療法) は,進行性または化学抵抗性HCCの生存効果を示しています.

さらに関連する動画

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

関連する実験動画

Last Updated: May 24, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

結論:

  • 監視による肝細胞癌の早期発見は,治癒性と生存率を改善します.
  • 治療の選択は,腫瘍の特徴,肝機能,患者の適格性に左右されます.
  • 進行中の病原性および標的療法に関する研究は,将来のHCC管理に有望である.